European shares eke out gains at open as healthcare stocks rebound
Sanofi rose 1.6% and GSK added 3.0% after a heavy selloff in the previous session on growing worries about U.S. litigation focused on a heartburn drug that contained a probable carcinogen.JPMorgan said it sees a stronger buying opportunity for Sanofi versus GSK, adding Sanofi would not be liable for any litigation damages.
